PJSC “Scientific-production centre “borshchahivskiy chemical pharmaceutical plant” (BCPP) plans until the end of 2018 to invest in the modernization of production 317 million, according to a press release from the company, citing commercial Director BCPP Eugene Owl.

“Despite the difficult economic situation in the country, we continue to implement their plans and are investing in their own development. So, by the end of 2018 we have planned 317 million UAH of investments into modernization of production”, – he said.

In addition, the press release said that the rating Agency “Credit-rating” confirmed long-term credit rating of BCCP.

As reported, at the end of 2016 BCPP increased net profit twice in comparison with the year 2015 – to 118,702 million. By the end of 2015 net profit of BCPP increased STA 35% to 59,3 million UAH.

In 2016, BCPP entered the top ten on the volume of pharmacy sales and 4.2% of the market .

In March 2015 Kyiv in million UAH 171,844 has sold its 30% stake BCPP pharmaceutical company “Darnytsia” (Kyiv).

In January 2016, the Antimonopoly Committee of Ukraine allowed the company “Darnitsa” to acquire more than 50% of the shares in BCPP. However, in April 2016, the Committee fined the company by 20.4 thousand UAH for the acquisition of 30% stake in the BCPP without permission of the regulator.

In mid-February 2017, the AMC reported a case of possible concentration of the Ukrainian pharmaceutical market CJSC “Darnitsa”, by purchasing shares of PJSC “Scientific-production centre “borshchahivskiy chemical pharmaceutical plant”.

In turn, BCPP repeatedly reported a slight increase in “Darnitsa” number of voting shares.

According to the state register, currently, the ultimate beneficiaries of BCPP are Tatiana Artemenko, Nikolay bespal’ko, Oleg Goloborodko, Gleb zagoriy and Eugene Owl.